BJL
GLUE icon

Brighton Jones LLC’s Monte Rosa Therapeutics GLUE Stock Holding History

Brighton Jones LLC’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Sell
9,746
-770
-7% -$14.5K ﹤0.01% 1174
2026
Q1 		$173K Buy
+10,516
New +$201K ﹤0.01% 1104
2025
Q3 		– Sell
-10,559
Closed -$47.6K – 1044
2025
Q2 		$47.6K Buy
+10,559
New +$47.1K ﹤0.01% 907

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Brighton Jones LLC's GLUE Position: Q2 2026 in Review

Brighton Jones LLC reduced its Monte Rosa Therapeutics (GLUE) stake by 7.3% in Q2 2026, selling an estimated $14.5K and leaving 9,746 shares worth $236K. The position accounts for ﹤0.01% of the portfolio, ranked #1174.

Brighton Jones LLC first reported a position in GLUE in Q2 2025 and has held it in 3 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Brighton Jones LLC held 9,746 shares of Monte Rosa Therapeutics worth $236K as of Q2 2026.
  • Brighton Jones LLC sold 770 Monte Rosa Therapeutics shares in Q2 2026, an estimated $14.5K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1174 holding.
  • Brighton Jones LLC first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.